Structure‐activity relationship study of neuroprotective complex I inhibitor CP2
Olga A. Petrova(Institute of Science and Technology Austria), Leonid A. Sazanov(Institute of Science and Technology Austria), Mark Ostroot(Mayo Clinic), Thi Kim Oanh Nguyen(Mayo Clinic), Graham Johnson(Royal Derby Hospital), Matthew J. Schellenberg(Mayo Clinic), Sergey A. Trushin(Office of Infectious Diseases), Eugenia Trushina(Mayo Clinic in Florida)
Cited by 1
Related Papers
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
|Journal of Alzheimer s Disease|2017|1.7k
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
|Nature Reviews Drug Discovery|2020|982
Mitigating the Psychological Impact of COVID-19 on Healthcare Workers: A Digital Learning Package
|International Journal of Environmental Research and Public Health|2020|685
Deficiency of terminal ADP‐ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease
|The EMBO Journal|2013|309